A Membrane Transporter Determines the Spectrum of Activity of a Potent DNA-Targeted Hybrid Anticancer Agent

05 June 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Cytotoxic drugs that are mechanistically distinct from current chemotherapies are attractive components of personalized combination regimens for combating aggressive forms of cancer. To gain insight into the cellular mechanism of a highly potent platinum–acridine hybrid agent, we performed a correlation analysis of NCI-60 compound screening results and gene expression profiles. We discovered a plasma membrane transporter, human multidrug and toxin extrusion protein 1 (hMATE1, SLC47A1), as the dominant pan-cancer predictor for cancer cell chemosensitivity to the hybrid agent. We have validated the role of hMATE1 using transporter inhibition, gene knockdown, and chemical sensitization assays. The results suggest that hMATE1 may have applications as a molecular marker to identify and target tumors that are likely to respond to platinum–acridines. Furthermore, enhancement of hMATE1 expression by epigenetic drugs emerges as a potential co-treatment strategy to sensitize tumor tissue to platinum–acridines and other anticancer drugs transported by hMATE1.


platinum-based chemotherapy
platinum-acridine hybrid agent
membrane transporter
solute carriers
multidrug and toxin extrusion protein
Epigenetic regulation
lung cancer
Renal Cancer
breast cancer
NSCLC cells
CNS cancer
prostate cancer
NCI 60 panel
Correlation Analysis
bioinformatic analysis
Combination therapy
precision medicine era
personalized oncology
drug transport
target validation

Supplementary materials

ChemRXiv SI
Table S5


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.